National audit of the use of fibrinogen concentrate to correct hypofibrinogenaemia

• Published in: Transfusion medicine (Oxford, England) England), 2012-10, Vol.22 (5), p.350-355
• Main Authors: Gollop, N. D., Chilcott, J., Benton, A., Rayment, R., Jones, J., Collins, P. W.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Afibrinogenemia - blood; Afibrinogenemia - drug therapy; Aged; Aged, 80 and over; Child; Child, Preschool; Coagulants - administration & dosage; coagulation; Cohort Studies; Female; fibrinogen; Fibrinogen - administration & dosage; haemorrhage; Hemorrhage - blood; Hemorrhage - drug therapy; Humans; hypofibrinogenaemia; Infant; Infant, Newborn; Male; Medical Audit; Middle Aged; Prospective Studies; United Kingdom
• ISSN: 0958-7578; 1365-3148
• DOI: 10.1111/j.1365-3148.2012.01168.x

SUMMARY Background Massive haemorrhage occurs in a variety of clinical settings resulting in consumptive and dilutional coagulopathies leading to hypofibrinogenaemia. Methods/Materials A prospective observational national cohort study was performed between November 2008 and June 2010 to collect safety data on the off‐label use of a fibrinogen concentrate to treat acquired hypofibrinogenaemia. Results A prospective cohort of 63 patients with varying causes of hypofibrinogenaemia resulted from this data collection. A single infusion of fibrinogen concentrate was given in 49 (77%) of patients studied and 12 received more than one infusion. The median inter‐quartile range (IQR) dose of fibrinogen infused was 49 (26–61) mg kg−1. The median (IQR) fibrinogen level before and after infusion was 0·9 (0·6–1·3) and 1·8 (1·4–4·3) g L−1, respectively (P